467 results on '"Romaguera, Jorge E."'
Search Results
102. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study
103. Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,
104. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study
105. Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up,
106. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia
107. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
108. Successful treatment of a free-moving abdominal mass with radiation therapy guided by cone-beam computed tomography: a case report
109. CT‐guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions
110. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
111. Cyclin D1 Polymorphisms as Predictive and Prognostic Molecular Markers in 90 Mantle Cell Lymphoma Patients Treated with R-HyperCVAD.
112. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone
113. Mantle cell lymphoma with a rare involvement of the testicle
114. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
115. CD20+ nodal marginal zone B-cell lymphoma with CD20–recurrence as an intracranial dural-based mass
116. Rosai-Dorfman disease misdiagnosed as active tuberculosis
117. A Pilot Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Classical Hodgkin Lymphoma (HL): Delivering Cross Fire Radiation by Targeting Reactive B Cells in the Microenvironment.
118. Activity of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in 22 Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).
119. ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study.
120. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma.
121. Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.
122. The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens
123. Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.
124. Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease
125. Outcomes Using Doxorubicin-Based Chemotherapy with or without Radiotherapy for Early-Stage Peripheral T-cell Lymphomas
126. Primary Effusion Lymphoma in an Hiv-Negative Patient with No Serologic Evidence of Kaposi's Sarcoma Virus
127. Detection of Chromosome 11q13 Breakpoints by Interphase Fluorescence In Situ Hybridization
128. Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients
129. The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas
130. Radiation therapy for stage I and II primary large B-cell lymphoma of the mediastinum
131. Contributors
132. Endocrine Characterization of Primary Mediastinal Lymphoma
133. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
134. 16-Year Experience at M. D. Anderson Cancer Center with Primary Ki-1 (CD30) Antigen Expression and Anaplastic Morphology in Adult Patients with Diffuse Large Cell Lymphoma
135. Primary mediastinal large cell lymphoma
136. Can we Identify Patients with Low Grade Lymphoma for Frontline ABMT?
137. Usefulness of Flow Cytometric Immunophenotyping for Bone Marrow Staging in Patients With Mantle Cell Lymphoma After Therapy.
138. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
139. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
140. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
141. CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions.
142. Expression of Eukaryotic Initiation Factor 4E Predicts Clinical Outcome in Patients With Mantle Cell Lymphoma Treated With Hyper-CVAD and Rituximab, Alternating With Rituximab, High-Dose Methotrexate, and Cytarabine.
143. Proliferation Predicts Failure-free Survival in Mantle Cell Lymphoma Patients Treated With Rituximab Plus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
144. Contributors
145. Dose-Related Safety and Immunogenicity of Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-Blind, Controlled Trial in Adult Patients with Non-Hodgkin B Cell Lymphoma.
146. Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings.
147. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
148. Correlation of Bcl-2Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma
149. Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma
150. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.